Skip to content
Back to outputs

"Dressed-up" naked plasmids: emerging vectors for non-viral gene therapy

Research output: Contribution to journalArticlepeer-review

Standard

"Dressed-up" naked plasmids: emerging vectors for non-viral gene therapy. / Gorecki, Darek.

In: Discovery Medicine, Vol. 6, No. 35, 2006, p. 191-197.

Research output: Contribution to journalArticlepeer-review

Harvard

Gorecki, D 2006, '"Dressed-up" naked plasmids: emerging vectors for non-viral gene therapy', Discovery Medicine, vol. 6, no. 35, pp. 191-197.

APA

Vancouver

Author

Gorecki, Darek. / "Dressed-up" naked plasmids: emerging vectors for non-viral gene therapy. In: Discovery Medicine. 2006 ; Vol. 6, No. 35. pp. 191-197.

Bibtex

@article{df3df6d7511e43c8b701a6968ddad59a,
title = "{"}Dressed-up{"} naked plasmids: emerging vectors for non-viral gene therapy",
abstract = "The non-viral vectors and targeting methods offer some specific advantages. These include better safety profiles (lower toxicity and non-infectious properties) and the capacity to transfer large genes and low production costs. The clinical usefulness of non-viral methods has been hindered by their relatively low gene delivery and transgene expression efficiencies. However, recent problems in clinical trials using viral vectors renewed interest in non-viral technologies, particularly that the properties of non-viral vectors make them appear closer to the traditional pharmaceutics.",
author = "Darek Gorecki",
year = "2006",
language = "English",
volume = "6",
pages = "191--197",
journal = "Discovery Medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "35",

}

RIS

TY - JOUR

T1 - "Dressed-up" naked plasmids: emerging vectors for non-viral gene therapy

AU - Gorecki, Darek

PY - 2006

Y1 - 2006

N2 - The non-viral vectors and targeting methods offer some specific advantages. These include better safety profiles (lower toxicity and non-infectious properties) and the capacity to transfer large genes and low production costs. The clinical usefulness of non-viral methods has been hindered by their relatively low gene delivery and transgene expression efficiencies. However, recent problems in clinical trials using viral vectors renewed interest in non-viral technologies, particularly that the properties of non-viral vectors make them appear closer to the traditional pharmaceutics.

AB - The non-viral vectors and targeting methods offer some specific advantages. These include better safety profiles (lower toxicity and non-infectious properties) and the capacity to transfer large genes and low production costs. The clinical usefulness of non-viral methods has been hindered by their relatively low gene delivery and transgene expression efficiencies. However, recent problems in clinical trials using viral vectors renewed interest in non-viral technologies, particularly that the properties of non-viral vectors make them appear closer to the traditional pharmaceutics.

M3 - Article

VL - 6

SP - 191

EP - 197

JO - Discovery Medicine

JF - Discovery Medicine

SN - 1539-6509

IS - 35

ER -

ID: 132230